Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 13 June 2025 PM
The dog's breakfast that was the path to funding for Novartis' Pluvicto has led Medicines Australia to take steps to regularise the HTA processes for radiopharmaceuticals.
The pharmaceutical industry peak body is keen to draw a line between the historical practice of providing unapproved radiotherapies as part of a clinical trial and the time when radiopharmaceuticals are approved and subsidised.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.